Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 + Glecirasib in KRAS G12C Mutated NSCLC
NCT07164170Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumipodlin in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
lumipodlin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07164170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164170.